Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Research & Development: 2009-2025

Historic Research & Development for Ani Pharmaceuticals (ANIP) over the last 17 years, with Sep 2025 value amounting to $12.3 million.

  • Ani Pharmaceuticals' Research & Development rose 21.48% to $12.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.0 million, marking a year-over-year increase of 48.27%. This contributed to the annual value of $44.6 million for FY2024, which is 30.03% up from last year.
  • Ani Pharmaceuticals' Research & Development amounted to $12.3 million in Q3 2025, which was down 25.59% from $16.5 million recorded in Q2 2025.
  • Ani Pharmaceuticals' 5-year Research & Development high stood at $16.6 million for Q4 2024, and its period low was $2.5 million during Q3 2021.
  • Its 3-year average for Research & Development is $10.8 million, with a median of $10.5 million in 2024.
  • Per our database at Business Quant, Ani Pharmaceuticals' Research & Development crashed by 53.22% in 2021 and then spiked by 211.77% in 2022.
  • Quarterly analysis of 5 years shows Ani Pharmaceuticals' Research & Development stood at $3.1 million in 2021, then soared by 66.31% to $5.2 million in 2022, then surged by 88.95% to $9.9 million in 2023, then skyrocketed by 68.70% to $16.6 million in 2024, then rose by 21.48% to $12.3 million in 2025.
  • Its last three reported values are $12.3 million in Q3 2025, $16.5 million for Q2 2025, and $10.6 million during Q1 2025.